Browsing Tag
Menin Inhibitor
2 posts
How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients
Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike.
Biomea Fusion reports positive 52-week phase II results showing non-chronic icovamenib treatment benefits in type 2 diabetes
Find out how Biomea Fusion’s 52-week phase II results point to a regenerative, non-chronic path for type 2 diabetes treatment.